Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Deals
  5. Alliances Collaborations Licensing
  6. Supply Agreement

Supply Agreement

Thumbnail
September 13, 2021

Valneva falls as UK contract axe falls

Valneva might have to look beyond the UK for vaccine sales after today's contract termination.

May 01, 2018

Bye, Repatha – price cut on Praluent wins exclusive Express Scripts deal

Vantage logo
November 13, 2015

Interview – Repatha risk-sharing could be just the beginning

Vantage logo
November 11, 2015

Philips ups stake in hospital game

Vantage logo
March 04, 2015

Bristol bets that yesterday’s prostate vaccine could score tomorrow

Vantage logo
January 20, 2015

Hep C price war evolves into value competition

Vantage logo
January 06, 2015

Payers’ defiance continues with Gilead CVS deal

Vantage logo
October 22, 2014

Bavarian Nordic leaps ahead in Ebola race

Vantage logo
August 11, 2014

For MannKind’s next trick, a big pharma partner

Vantage logo
July 23, 2014

Vantage point – US push for bundled payments prompts pharma-medtech collaboration

Vantage logo
September 16, 2013

Fresenius deal underlines growing importance of hospital sector

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

July 04, 2022

Pharma Drivers eBook Part 1

June 16, 2022

Vantage Top 10 Most Read Report

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.